FDA Advisers Consider Novavax COVID-19 Vaccine This Week FDA Advisers Consider Novavax COVID-19 Vaccine This Week
An FDA panel will consider Novavax ' s COVID two-dose, protein-based vaccine this week, looking at some reports of adverse reactions, including rare events of myocarditis and pericarditis.WebMD Health News
Source: Medscape Infectious Diseases Headlines - Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news
More News: Covid Vaccine | COVID-19 | Health | Infectious Diseases | Myocarditis | Pericarditis | Vaccines